CLAIMS

1. Use of a composition in the manufacture of a medicament for the treatment, prevention, stabilisation, delay in onset and/or reduction of the symptoms of age-related and/or degenerative diseases in a subject, wherein the composition comprising a combination of

- a biguanide, and/or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, and

- an acetylcholinesterase inhibitor, and/or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, wherein the biguanide is metformin;

and wherein the age-related and/or degenerative diseases are diseases of the neuro-musculoskeletal system, frailty, and/or inflammatory liver disease.

2. The use according to any of the preceding claims wherein the age-related and/or degenerative diseases of the neuro-musculoskeletal system are selected from the group comprising extrapyramidal and movement disorders, diseases of myoneural junction and muscle, systemic atrophies primarily affecting the central nervous system, muscular dystrophy, duchenne muscular dystrophy, spinal muscular atrophy and related diseases, motor neuron diseases such as amyotrophic lateral sclerosis, abnormal involuntary movements, abnormalities of gait and mobility, ataxia, and sarcopenia.

3 The use according to any of the preceding claims wherein the age-related and/or degenerative diseases of the neuro-musculoskeletal system are extrapyramidal and movement disorders, diseases of myoneural junction and muscle, systemic atrophies primarily affecting the central nervous system, muscular dystrophy, duchenne muscular dystrophy, spinal muscular atrophy, motor neuron diseases such as amyotrophic lateral sclerosis, abnormal involuntary movements, abnormalities of gait and mobility, or ataxia.

4. The use according to claim 1 to 2 wherein the age-related and/or degenerative disease of the neuro-musculoskeletal system is sarcopenia.

5. The use according to claim 1 wherein the age-related and/or degenerative diseases of the neuro-musculoskeletal system are mitochondrial associated neuromusculoskeletal diseases selected from central core disease and Optic Atrophy 1 (OPA1) associated diseases, wherein said OPA1 associated diseases are selected from optic atrophy, OPA1 associated hypertension, and OPA1 associated atrophy.

6. The use according to any of the preceding claims wherein the acetylcholinesterase inhibitor is selected from the group comprising galantamine, donepezil, rivastigmine and memantine.

7. The use according to claim 6, wherein the acetylcholinesterase inhibitor is galantamine.

8. Non-therapeutic use of a composition for prevention, stabilization and/or reduction of age-related complaints and/or degenerative complaints, said comprising a combination of:

- a biguanide, or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, and

- an acetylcholinesterase inhibitor, or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, wherein the biguanide is metformin; and

wherein the age-related complaints and/or degenerative complaints are selected from the group comprising muscular weakness, decreased muscular strength, neuro-muscular degeneration, and impaired mobility.

9. Non-therapeutic use of a composition for improving a measure of life span and/or health span, said composition comprising a combination of:

- a biguanide, or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, and

- an acetylcholinesterase inhibitor, an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof, wherein the biguanide is metformin and the acetylcholinesterase inhibitor is galantamine, and

wherein the improved measure of life span and/or health span is selected from the group comprising the mitigation or stabilisation of age-related complaints, , relative to the condition of the subject before administration of the composition or relative to a control population, and wherein age-related complaints and/or degenerative complaints are selected from the group comprising muscular weakness, decreased muscular strength, neuro-muscular degeneration, impaired mobility, impaired immune response, metabolic imbalance, general weakness.

10. The non-therapeutic use of the composition according to claim 8 or 9, wherein age-related complaints and/or degenerative complaints are selected from the group comprising muscular weakness, decreased muscular strength, neuro-muscular degeneration, and impaired mobility.

11. The non-therapeutic use of the composition according to claim 8 or 9 wherein the age-related complaint and/or degenerative complaint is general weakness.

12. The non-therapeutic use of the composition according to anyone of claims 8, or 10 -11, wherein the acetylcholinesterase inhibitor is selected from the group comprising galantamine, donepezil, rivastigmine, and memantine.

13. The non-therapeutic use of the composition according to claim 12 wherein the acetylcholinesterase inhibitor is galantamine.

14. The use according to any one of claims 1 to 7, or the non-therapeutic use of the composition according to any one of claims 8 to 12, wherein the biguanide and the

acetylcholinesterase inhibitor are to be administered in a subtherapeutic dose to the subject.

15. The use according to any one of claims 1 to 7 or the non-therapeutic use of the composition according to anyone of claims 8 to 13, wherein the subject is a human subject.

16. The use according to any one of claims 1 to 7 or the non-therapeutic use of the composition according to anyone of claims 8 to 13, wherein the biguanide and the acetylcholinesterase inhibitor or their N-oxide, hydrate, pharmaceutically acceptable salt or solvate are separately formulated into pharmaceutical compositions or formulated in a single pharmaceutical composition.